Despite the success of coronary stent implantations in the last decade, in-stent restenosis due to neointimal hyperplasia remains a problem to overcome. Neointimal hyperplasia is a vascular response to stent injury and mainly consists of proliferation of smooth muscle cells and deposition of extracellular matrix. Recently, local drug delivery has been advocated as a potential strategy to prevent in-stent restenosis. Unprecedented results have been obtained in early clinical studies on sirolimus-eluting and paclitaxel-eluting stents. Trials using various pharmaceutical coatings on different coronary stents are ongoing. More types of drug-eluting stents are expected on the market in the near future. Meanwhile, the evaluation of drug-eluting stents is entering the second phase in which the safety and efficacy in more complex lesion subsets and different clinical presentations are being investigated. Results including cost-benefit analyses are expected to have a tremendous impact on the practice of interventional cardiology in the next decade.
Get full access to this article
View all access options for this article.
References
1.
SerruysPWLuijtenHEBeattKJGeuskensRde FeyterPJvan den BrandM. Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation1988;77:361–71.
2.
NobuyoshiMKimuraTNosakaHMiokaSUenoKYokoiH. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 229 patients. J Am Coll Cardiol1988;12:616–23.
3.
FischmanDLLeonMBBaimDSSchatzRASavageMPPennI. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med1994;331:496–501.
4.
SerruysPWde JaegerePKiemeneijFMacayaCRutschWHeyndrickxG. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med1994;331:489–95.
5.
McBrideWLangeRAHillisLD. Restenosis after successful coronary angioplasty. Pathophysiology and prevention. N Engl J Med1988;318:1734–7.
6.
WaxmanSSassowerMAMittlemanMAZarichSMiyamotoAManzoKS. Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non-Q-wave myocardial infarction. Circulation1996;93:2106–13.
7.
OlsonNEChaoSLindnerVReidyMA. Intimal smooth muscle cell proliferation after balloon catheter injury. The role of basic fibroblast growth factor. Am J Pathol1992;140:1017–23.
8.
ScottNACipollaGDRossCEDunnBMartinFHSimonetL. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation1996;93:2178–87.
9.
RensingBJHermansWRBeattKJLaarmanGJSuryapranataHvan den BrandM. Quantitative angiographic assessment of elastic recoil after percutaneous transluminal coronary angioplasty. Am J Cardiol1990;66:1039–44.
10.
PasterkampGBorstCGussenhovenEJMaliWPPostMJTheSH. Remodeling of De Novo atherosclerotic lesions in femoral arteries: Impact on mechanism of balloon angioplasty. J Am Coll Cardiol1995;26:422–8.
11.
TeirsteinPS. Living the dream of no restenosis. Circulation2001;104:1996–8.
12.
van der GiessenWJLincoffAMSchwartzRSvan BeusekomHMSerruysPWHolmesDRJr. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation1996;94:1690–7.
13.
HaudeMKonorzaTFKalninsUErglisASaunamakiKGlogarHD. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation2003;107:1265–70.
14.
WhelanDMvan BeusekomHMvan der GiessenWJ. Mechanisms of drug loading and release kinetics. Semin Interv Cardiol1998;3:127–31.
15.
HwangCWWuDEdelmanER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation2001;104:600–5.
16.
MohacsiPJTullerDHulligerBWijngaardPL. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant1997;16:484–92.
17.
DrachmanDEEdelmanERSeifertPGroothuisARBornsteinDAKamathKR. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months. J Am Coll Cardiol2000;36:2325–32.
18.
HongMKKornowskiRBramwellORaghebAOLeonMB. Paclitaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis2001;12:513–5.
19.
HeldmanAWChengLJenkinsGMHellerPFKimDWWareMJr. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289–95.
20.
FarbAHellerPFShroffSChengLKolodgieFDCarterAJ. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation2001;104:473–9.
21.
ParkSJShimWHHoDSRaiznerAEParkSWHongMK. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med2003;348:1537–45.
22.
HongMKMintzGSLeeCWSongJMHanKHKangDH. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: A serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation2003;107:517–20.
23.
GershlickADe ScheerderIChevalierBStephens-LloydACamenzindEVrintsC. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation2004;109:487–93.
24.
GrubeESilberSHauptmannKEMuellerRBuellesfeldLGerckensU. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation2003;107:38–42.
25.
ColomboADrzewieckiJBanningAGrubeEHauptmannKSilberS. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation2003;108:788–94.
26.
StoneGWEllisSGCoxDAHermillerJO'ShaughnessyCMannJT. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med2004;350:221–31.
27.
TanabeKSerruysPWGrubeESmitsPCSelbachGvan der GiessenWJ. TAXUS III Trial: In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation2003;107:559–64.
28.
HondaYGrubeEde La FuenteLMYockPGStertzerSHFitzgeraldPJ. Novel drug-delivery stent: Intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation2001;104:380–3.
29.
KataokaTGrubeEHondaYMorinoYHurSHBonneauHN. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: An intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation2002;106:1788–93.
30.
GalloRPadureanAJayaramanTMarxSRoqueMAdelmanS. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation1999;99:2164–70.
31.
HalloranPF. Sirolimus and cyclosporin for renal transplantation. Lancet2000;356:179–80.
32.
PoonMBadimonJJFusterV. Overcoming restenosis with sirolimus: From alphabet soup to clinical reality. Lancet2002;359:619–22.
33.
SuzukiTKopiaGHayashiSBaileyLRLlanosGWilenskyR. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation2001;104:1188–93.
34.
SousaJECostaMAAbizaidAAbizaidASFeresFPintoIM. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation2001;103:192–5.
35.
SousaJECostaMAAbizaidACRensingBJAbizaidASTanajuraLF. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation2001;104:2007–11.
36.
SousaJECostaMASousaAG. What is “the matter” with restenosis in 2002?Circulation2002;105:2932–3.
37.
TanabeKDegertekinMRegarELigthartJMvan der GiessenWJSerruysPW. No delayed restenosis at 18 months after implantation of sirolimus-eluting stent. Catheter Cardiovasc Interv2002;57:65–8.
38.
MoriceMCSerruysPWSousaJEFajadetJHayashiBan EPerinM. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med2002;346:1773–80.
39.
SerruysPWDegertekinMTanabeKAbizaidASousaJEColomboA. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 2002;106:798–803.
40.
MosesJWLeonMBPopmaJJFitzgeraldPJHolmesDRO'ShaughnessyC. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med2003;349:1315–23.
41.
SchoferJSchluterMGershlickAHWijnsWGarciaESchampaertE. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet2003;362:1093–9.
42.
SchampaertECohenEASchluterMReevesFTraboulsiMTitleLM. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol2004;43:1110–5.
43.
LemosPASerruysPWvan DomburgRTSaiaFArampatzisCAHoyeA. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation2004;109:190–5.
44.
GrubeESonodaSIkenoFHondaYKarSChanC. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation2004;109:2168–71.
45.
LiuXHuangYHanetCVandormaelMLegrandVDensJ. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): A first-in-human multicenter pilot trial. Catheter Cardiovasc Interv2003;60:172–9.
46.
BuellesfeldLGrubeE. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?Herz2004;29:167–70.
47.
Van BelleETioFOChenDMaillardLChenDKearneyM. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol1997;29:1371–9.
48.
SwansonNHogrefeKJavedQMalikNGershlickAH. Vascular endothelial growth factor (VEGF)-eluting stents: In vivo effects on thrombosis, endothelialization and intimal hyperplasia. J Invasive Cardiol2003;15:688–92.
49.
de SmetBJde KleijnDHanemaaijerRVerheijenJHRobertusLvan Der HelmYJ. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: A study in the atherosclerotic Yucatan micropig. Circulation2000;101:2962–7.
50.
AbizaidAAlbertalMCostaMAAbizaidASStaicoRFeresF. First human experience with the 17-beta-estradiol-eluting stent: The Estrogen And Stents To Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol2004;43:1118–21.
51.
DegertekinMSerruysPWTanabeKLeeCHSousaJEColomboA. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: An intravascular ultrasound analysis. Circulation2003;108:2747–50.
52.
SerruysPWDegertekinMTanabeKRussellMEGuagliumiGWebbJ. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: Serial intravascular ultrasound analysis from the TAXUS II trial. Circulation2004;109:627–33.
53.
CohenDJBakhaiAShiCGithioraLLavelleTBerezinRH. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation2004;110:508–14.
